Matthew P. Goetz, M.D.

My research focus in the area of estrogen receptor positive breast cancer. My work is performed in collaboration with the laboratory of Matthew Ames, Ph.D. Additional key collaborators include James Ingle, M.D. (PI, Mayo Breast SPORE); Richard Weinshilboum, M.D. (PI, Mayo PGRN); and Thomas Spelsberg, Ph.D.

A notable area of our focus is the pharmacogenetics of tamoxifen. I am principal investigator of ongoing studies (1R01 CA133049-01) focused on the pharmacogenetics of tamoxifen biotransformation.

Additionally, we are studying the role of the 13C - DM breath test as a marker of CYP2D6 activity in tamoxifen treated patients in collaboration with Physical Sciences, Inc. and Cambridge Isotope Laboratories, Inc (R43 CA110874-03)

In collaboration with the NCI/DTP, we are developing a novel formulation of endoxifen (endoxifen hydrochloride) for the treatment of ER positive breast cancer. Initial pre-clinical toxicology and pharmacology studies were completed in 2010 and first-in-human phase I studies of endoxifen hydrochloride will commence in 2011 at Mayo Clinic and NCI.

Additionally, I am a funded investigator within the Mayo Pharmacogenetics Research Network grant (Richard Weinshilboum, PI), and the Mayo Clinic Phase I program. I am a past recipient of a Mayo Breast Cancer SPORE Career development award and Paul Calabresi Scholar Award (K-12).